Related Experiment Video
Updated: Jan 3, 2026
06:18
Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue
Published on: June 21, 2018
11.9K
Lactate dehydrogenase in dermatology practice.
A Livesey1, F Garty1, A R Shipman1
1Dermatology Department, St Mary's Hospital, Portsmouth, UK.
Clinical and Experimental Dermatology
|November 23, 2019
Summary
Lactate dehydrogenase (LDH) is a key prognostic marker in dermatology for cutaneous lymphoma. Elevated LDH levels, caused by cell damage, are reviewed alongside diagnostic and staging guidelines for this cancer.
Area of Science:
- Biochemistry
- Oncology
- Dermatology
Background:
- Lactate dehydrogenase (LDH) is an intracellular enzyme central to anaerobic glycolysis.
- LDH is ubiquitously expressed, with cell damage leading to its release into circulation.
- Elevated LDH levels have multiple potential causes, necessitating careful interpretation.
Purpose of the Study:
- To review the utility of lactate dehydrogenase (LDH) in dermatological practice.
- To highlight LDH's role as a prognostic marker for cutaneous lymphoma.
- To discuss current diagnostic and staging guidelines relevant to LDH.
Main Methods:
- Literature review of studies on lactate dehydrogenase (LDH) in dermatology.
- Analysis of LDH's role in anaerobic glycolysis and cellular damage.
- Examination of diagnostic and staging protocols for cutaneous lymphoma.
Main Results:
- Lactate dehydrogenase (LDH) serves as a significant prognostic indicator for cutaneous lymphoma.
- Understanding LDH's origin from cell damage is crucial for interpreting elevated levels.
- Current guidelines incorporate LDH in the assessment of cutaneous lymphoma.
Conclusions:
- Lactate dehydrogenase (LDH) is a valuable marker in dermatology, especially for cutaneous lymphoma prognosis.
- The interpretation of LDH levels requires consideration of its multiple causes.
- Adherence to diagnostic and staging guidelines is essential for effective patient management.
